HOME >> BIOLOGY >> NEWS
Blocking a premature aging syndrome with anticancer drugs

A class of anticancer drugs currently being evaluated in phase 3 clinical trials may also be an effective treatment for Hutchinson-Gilford progeria syndrome (HGPS), a fatal genetic disorder that causes premature aging. If upcoming studies in a HGPS mouse model validate the results of experiments in cultured cells in the laboratory, a clinical trial of these drugs in HGPS children may begin as early as next spring.

Brian Capell, a New York University medical student participating in the Howard Hughes Medical Institute/National Institutes of Health Research Scholars Program and the first author of the study, reported the findings in the August 29, 2005, issue of the Proceedings of the National Academy of Sciences. The HHMI-NIH Research Scholars Program gives outstanding medical and dental students the opportunity to conduct biomedical research under the direct mentorship of senior NIH research scientists.

Although HGPS is a rare disease that affects only one child in 4 million, the disease has received wide publicity due to its striking nature. Children born with HGPS appear normal, but they experience growth retardation and show symptoms of accelerated aging -- namely hair loss, skin wrinkling, and fat loss -- around the first year of age. Accelerated cardiovascular disease also ensues, which typically causes death around age 12.

In 2003, researchers in Francis Collins's lab at the National Human Genome Research Institute discovered that mutations in the lamin A (LMNA) gene cause HGPS. The discovery has prompted renewed interest among researchers to study this rare syndrome.

When Capell entered Collins's lab in July 2004, he immediately set his sights on understanding the molecular basis of HGPS. "What really interested me in this research in the first place were the potential links to aging and atherosclerotic disease," says Capell. Indeed, understanding HGPS at the molecular level may illuminate general processes
'"/>

Contact: Jennifer Donovan
donovanj@hhmi.org
301-215-8859
Howard Hughes Medical Institute
29-Aug-2005


Page: 1 2 3

Related biology news :

1. Blocking beta1-integrin to treat cancer
2. Blocking blood vessels provides new option for large group of advanced lung cancer patients
3. Blocking COX-1 slows tumor growth in mice
4. Blocking PLK-1 to beat bladder cancer
5. Blocking neurodegeneration by radiation and bone marrow transfer prevents inherited glaucoma in mice
6. Blocking cell signaling can stymie viral infections, study shows
7. Blocking cell suicide switch fails to stop prion damage in mouse brains
8. Promising protein may prevent eye damage in premature babies
9. Study assesses lung treatments for premature babies
10. Different approach needed to protect brains of premature infants
11. Improving outcomes in premature births

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/1/2020)... VENICE, Calif. (PRWEB) , ... July 01, 2020 ... ... focused on building awareness and solutions for glioblastoma—the most common and aggressive adult ... and Lisa Haile, JD, PhD. Senior Fellows are charged with supporting the organization’s ...
(Date:6/23/2020)... ... June 23, 2020 , ... First Aid Africa, a ... UK supplier and manufacturer of innovative portable renewable energy equipment, have announced the ... against the COVID-19 pandemic in Zambia. , One of Renovagen’s FAST FOLD portable ...
(Date:6/19/2020)... ... June 18, 2020 , ... ... for Data Decisions,” for pharmaceutical and biotech executives, laboratory managers, scientists, researchers ... scientific instruments and laboratory equipment from dozens of manufacturers into their lab. ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... HOUSTON (PRWEB) , ... August ... ... a biopharmaceutical cold chain validation engineering firm, is making available for ... driving the need to incorporate concurrent transport simulation testing into today’s biologics ...
(Date:8/3/2020)... ... August 03, 2020 , ... ... announced Jim Corrigan, President and CEO has been named one of the 100 ... of industry sectors, PharmaVoice 100 honorees are selected based on how they have ...
(Date:7/31/2020)... (PRWEB) , ... July 29, 2020 , ... ... today announced the launch of its new tagline, “BUILDING FOR LIFE.” The adoption ... industry and around the globe, requiring fast track capacity to provide patients with ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, ... have entered into a strategic partnership whereby Catalent will provide support for the ...
Breaking Biology Technology:
Cached News: